Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 85Specimen Handling 66Prednisone 64Androgen Antagonists 59Abiraterone Acetate 58apalutamide 56Radiosurgery 52darolutamide 48Radiotherapy 47Leuprolide 47abiraterone 45Docetaxel 42Pluvicto 32Biopsy 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Radiation 30relugolix 28Surveys and Questionnaires 28gallium 68 PSMA-11 26Standard of Care 26pembrolizumab 25Goserelin 25Triptorelin Pamoate 24Gonadotropin-Releasing Hormone 23bicalutamide 22Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × PROSTVAC × 1 year × Clear all
NCT02649855 2026-04-29

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
74 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

NCT03315871 2025-06-19

Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
40 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡